



INDOCO REMEDIES LTD

## indoco remedies limited

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACRUZ (EAST), MUMBAI - 400 098 (INDIA) ● Website : [www.indoco.com](http://www.indoco.com)  
PHONES : (91-22) 3386 1000 / 3386 1250 ● FAX : (91-22) 2652 3067 / 2652 3976 ● CIN : L85190MH1947PLC005913

January 28, 2019

To  
**The Listing Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra – Kurla Complex  
Bandra (East)  
Mumbai – 400 051


To  
The Listing Department  
**Bombay Stock Exchange Limited**  
Floor 25, P. J. Towers,  
Dalal Street,  
Mumbai – 400 001

Dear Sirs,

**Sub: Disclosure Under Regulation 30 of LODR Regulations 2015**  
**USFDA Inspection - Updates**

Further to our letter dated 18<sup>th</sup> January, 2019 on the above subject, attached please find a copy of the Press Release giving updates on the status of the Inspection.

**For Indoco Remedies Limited**

  
**Jayshankar Menon**  
Company Secretary

## PRESS RELEASE

### USDFA concludes audit at Indoco's Goa Plant I

**Mumbai, January 28, 2019:** The US Food and Drug Administration (USFDA) audit, which started on 17<sup>th</sup> January, 2019 at Indoco's Goa Plant I (Oral Dosages Facility), concluded on 25<sup>th</sup> January, 2019 with the Regulatory Agency issuing 6 observations (483s) to the site. None of these observations are critical in nature. The Company will respond to these observations within the stipulated time of 15 days.

**Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited** commented, "Most of these observations are related to areas of improvement needed in documentation and review procedures. These observations / recommendations will help us further improve our quality systems in the plant, which in turn, will give a boost to revenues from the US market".

The site will continue to supply to US market, the existing approved product and await approval of pending ANDAs.

#### About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 161 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

#### For Media Inquiries Please Contact:

**Vilas V. Nagare**

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com) / [corpcom@indoco.com](mailto:corpcom@indoco.com)